Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc., a leading player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in developing innovative therapies for urological conditions, focusing on unmet medical needs. With a strong presence in the US and expanding operations in key international markets, Urigen is dedicated to advancing patient care through its unique product offerings. The company’s flagship product, a proprietary formulation for the treatment of bladder pain syndrome, stands out for its targeted approach and efficacy. Recognised for its commitment to research and development, Urigen Pharmaceuticals has established a solid market position, contributing to advancements in urology and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Urigen Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Urigen Pharmaceuticals, Inc.'s score of 18 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Urigen Pharmaceuticals, Inc.'s reported carbon emissions
Urigen Pharmaceuticals, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon footprint in terms of kg CO2e across Scope 1, 2, or 3 emissions. While the company has not disclosed any climate commitments or initiatives aimed at reducing carbon emissions, it is essential for organisations in the pharmaceutical sector to engage in sustainable practices and set measurable targets to mitigate their environmental impact. The absence of data highlights an opportunity for Urigen Pharmaceuticals to enhance transparency and contribute to industry-wide efforts in addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Urigen Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
